{"id":2,"date":"2023-04-26T09:00:44","date_gmt":"2023-04-26T07:00:44","guid":{"rendered":"https:\/\/webs.uab.cat\/midalab\/?page_id=2"},"modified":"2025-01-12T21:35:30","modified_gmt":"2025-01-12T19:35:30","slug":"description","status":"publish","type":"page","link":"https:\/\/webs.uab.cat\/midalab\/","title":{"rendered":"The MIDAlab"},"content":{"rendered":"\n<p>The MIDAlab, established in November 2021, is under the leadership of Dr Margarita Juli\u00e0 Sap\u00e9. The team is currently situated at the <a rel=\"noreferrer noopener\" href=\"https:\/\/ibb.uab.cat\/\" target=\"_blank\">Institute of Biotechnology and Biomedicine (IBB)<\/a> of the UAB.<\/p>\n\n\n\n<p>Dr. Juli\u00e0 holds an extensive career at the <a rel=\"noreferrer noopener\" href=\"https:\/\/www.uab.cat\/ca\/bioquimica\" target=\"_blank\">Department of Biochemistry and Molecular Biology<\/a> of the <a rel=\"noreferrer noopener\" href=\"https:\/\/www.uab.cat\/web\/faculty-of-biosciences-1345721820908.html\" target=\"_blank\">Biosciences Faculty<\/a>, having been a member of the <a rel=\"noreferrer noopener\" href=\"https:\/\/webs.uab.cat\/gabrmn\/\" target=\"_blank\">GABRMN group<\/a> within the same deparment during 21 years, until the inception of MIDAlab. <\/p>\n\n\n\n<p>The MIDAlab maintains close ties to the <a rel=\"noreferrer noopener\" href=\"https:\/\/webs.uab.cat\/gabrmn\/\" target=\"_blank\">GABRMN<\/a>. The members of both MIDAlab and the GABRMN are part of various scientific networks, including: <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The <a href=\"https:\/\/www.ciberisciii.es\/\" target=\"_blank\" rel=\"noreferrer noopener\">Centro de Investigaci\u00f3n en Red (CIBER)<\/a> in <a href=\"https:\/\/www.ciber-bbn.es\/en\" target=\"_blank\" rel=\"noreferrer noopener\">Bioengineering, Biomaterials and Nanotechnology (CIBER-BBN)<\/a>, specifically through group <a href=\"https:\/\/www.ciber-bbn.es\/en\/groups\/research-group?id=3562\" target=\"_blank\" rel=\"noreferrer noopener\">CB06\/01\/0010 <\/a>, led by Dr. Ana Paula Candiota,<\/li>\n\n\n\n<li>The <a rel=\"noreferrer noopener\" href=\"http:\/\/nanbiosis.es\" data-type=\"URL\" target=\"_blank\">Nanbiosis<\/a> <a rel=\"noreferrer noopener\" href=\"https:\/\/www.nanbiosis.es\/portfolio\/u25-nmr-biomedical-application-i\/\" data-type=\"page\" target=\"_blank\">U25. NMR: Biomedical Applications I<\/a>  platform.<\/li>\n\n\n\n<li>The SGR group <a rel=\"noreferrer noopener\" href=\"https:\/\/portalrecerca.uab.cat\/en\/organisations\/n-tetrascannoves-ter%C3%A0pies-pel-tractament-i-seguiment-no-invasiu-d\" target=\"_blank\">N-TETRASCAN<\/a>  headed by Dr. Julia Lorenzo. <\/li>\n\n\n\n<li>The <a rel=\"noreferrer noopener\" href=\"https:\/\/xartecsalut.com\/\" target=\"_blank\">Xartec Salut<\/a> network, through the SINTTC group led by Dr. Margarita Juli\u00e0.<\/li>\n<\/ul>\n\n\n\n<p><strong>MIDAlab RESEARCH INTERESTS<\/strong><\/p>\n\n\n\n<p>MIDAlab&#8217;s research interests primarily revolve around the application of data science and machine learning (ML) to the study of metabolism. <\/p>\n\n\n\n<p>In particular, we use  <strong>metabolomics combined with imaging data to discover diagnostic and prognostic biomarkers for brain diseases<\/strong>.<\/p>\n\n\n\n<p>We employ metabolomics in conjunction with imaging data to identify diagnostic and prognostic biomarkers for brain diseases. The primary focus is on the analysis of magnetic resonance (MR) data, particularly <strong>magnetic resonance spectroscopy (MRS)<\/strong>, either alone or in combination with other MR-related imaging modalities. Clinical data from collaborating hospitals and clinical centers, as well as preclinical data, are used.<\/p>\n\n\n\n<p>In contrast to traditional MRS analysis methodologies based on peak quantification, MIDAlab excels in applying a variety of supervised, non-supervised and semi-supervised techniques, both for classification and for the discovery of hidden patterns in the data. <\/p>\n\n\n\n<p>Although the current emphasis is on brain tumors, MIDAlab extends its analytical approach to neurodegenerative diseases through scientific collaborations.<\/p>\n\n\n\n<p><br><strong>MIDAlab STRATEGIC OBJECTIVES<\/strong><br>MIDAlab&#8217;s long-term objective is to bridge the gap between scientific findings based on MRS and their practical application in clinical settings. We aim to aid clinicians in adopting MRS more readily, by developing user-friendly decision-support tools (DSS) to unlock the full potential of MRS as a diagnostic modality in clinical practice.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"617\" height=\"486\" src=\"https:\/\/webs.uab.cat\/midalab\/wp-content\/uploads\/sites\/322\/2023\/04\/The-integrated-framework-MIDAlab-1.jpg\" alt=\"\" class=\"wp-image-22\" srcset=\"https:\/\/webs.uab.cat\/midalab\/wp-content\/uploads\/sites\/322\/2023\/04\/The-integrated-framework-MIDAlab-1.jpg 617w, https:\/\/webs.uab.cat\/midalab\/wp-content\/uploads\/sites\/322\/2023\/04\/The-integrated-framework-MIDAlab-1-300x236.jpg 300w\" sizes=\"auto, (max-width: 617px) 100vw, 617px\" \/><\/figure>\n\n\n\n<p><strong>MIDAlab MAIN RESEARCH LINES<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Using <strong>MRS data<\/strong> and <strong>imaging <\/strong>to find <strong>diagnostic <\/strong>and <strong>prognostic biomarkers <\/strong>in brain tumours.<\/li>\n\n\n\n<li>Applying <strong>advanced machine learning (ML) tools<\/strong> to in vivo MRS data for:\n<ul class=\"wp-block-list\">\n<li><strong>Biomarker discovery<\/strong><\/li>\n\n\n\n<li><strong>Automated quality control<\/strong><\/li>\n<\/ul>\n<\/li>\n\n\n\n<li>Developing and testing <strong>user-friendly software tools for clinical applications<\/strong>.<\/li>\n<\/ol>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"399\" src=\"https:\/\/webs.uab.cat\/midalab\/wp-content\/uploads\/sites\/322\/2023\/04\/QC-MIDAlab-1024x399.png\" alt=\"\" class=\"wp-image-24\" srcset=\"https:\/\/webs.uab.cat\/midalab\/wp-content\/uploads\/sites\/322\/2023\/04\/QC-MIDAlab-1024x399.png 1024w, https:\/\/webs.uab.cat\/midalab\/wp-content\/uploads\/sites\/322\/2023\/04\/QC-MIDAlab-300x117.png 300w, https:\/\/webs.uab.cat\/midalab\/wp-content\/uploads\/sites\/322\/2023\/04\/QC-MIDAlab-768x300.png 768w, https:\/\/webs.uab.cat\/midalab\/wp-content\/uploads\/sites\/322\/2023\/04\/QC-MIDAlab.png 1064w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>The MIDAlab, established in November 2021, is under the leadership of Dr Margarita Juli\u00e0 Sap\u00e9. The team is currently situated at the Institute of Biotechnology and Biomedicine (IBB) of the UAB. Dr. Juli\u00e0 holds an extensive career at the Department of Biochemistry and Molecular Biology of the Biosciences Faculty, having been a member of the [&hellip;]<\/p>\n","protected":false},"author":2550,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"sidebar.php","meta":{"footnotes":""},"class_list":["post-2","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/webs.uab.cat\/midalab\/wp-json\/wp\/v2\/pages\/2","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/webs.uab.cat\/midalab\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/webs.uab.cat\/midalab\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/webs.uab.cat\/midalab\/wp-json\/wp\/v2\/users\/2550"}],"replies":[{"embeddable":true,"href":"https:\/\/webs.uab.cat\/midalab\/wp-json\/wp\/v2\/comments?post=2"}],"version-history":[{"count":52,"href":"https:\/\/webs.uab.cat\/midalab\/wp-json\/wp\/v2\/pages\/2\/revisions"}],"predecessor-version":[{"id":207,"href":"https:\/\/webs.uab.cat\/midalab\/wp-json\/wp\/v2\/pages\/2\/revisions\/207"}],"wp:attachment":[{"href":"https:\/\/webs.uab.cat\/midalab\/wp-json\/wp\/v2\/media?parent=2"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}